The Cooper Companies, Inc. (COO) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call indicates positive sentiment with strong product development, optimistic revenue guidance, and expected market share gains. The strategic plans for MyDAY and MiSight, along with anticipated operating margin expansion and free cash flow improvements, contribute to this outlook. Despite some gross margin pressure, the overall sentiment from the call, including analyst reactions, suggests a positive impact on stock price.
Key Financial Performance
Consolidated Revenues $1.065 billion, up 4.6% year-over-year or up 3.4% organically. Reasons for change include improved global availability of MyDay lenses and strong performance in certain regions.
Operating Margins Improved meaningfully to a 27% margin, with operating income increasing by 9%. This was driven by disciplined cost management and efficiency improvements.
Non-GAAP Earnings Grew 11% to $1.15. Reasons include significant cost savings from reorganization and operational efficiency.
Free Cash Flow $150 million in Q4, beating expectations. Reasons include strong earnings and disciplined capital expenditure management.
CooperVision Revenue $710 million, up 4.9% or 3.2% organically. Growth was driven by improved availability of MyDay lenses, offset by market softness in China and EMEA.
CooperSurgical Revenue $356 million, up 4% or 3.9% organically. Growth was driven by solid execution, market share gains in EMEA, and strong global genomics performance.
Gross Margin Declined marginally to 66.2%, driven by tariffs and product mix, partially offset by positive foreign exchange.
Interest Expense $23.7 million, with an effective tax rate of 14.2%. No specific reasons for change were mentioned.
Net Debt $2.4 billion, improving the bank-defined leverage ratio to 1.76x. Reasons include strong free cash flow and disciplined financial management.
PARAGARD Sales Grew 16%, driven by strong demand for the single-hand inserter upgrade launched earlier this year.
MiSight Revenue Grew 37%, driven by robust performance in the Americas and EMEA, supported by back-to-school campaigns and new pricing models.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
MyDay premium daily silicone hydrogel lens portfolio: Accelerated global rollout with momentum building. Upcoming product launches expected to strengthen positioning and drive revenue growth in fiscal 2026.
MiSight: Delivered 37% growth, driven by strong performance in the Americas and EMEA. Upcoming launches in Japan and Europe expected to sustain growth.
clariti: Repositioning in Asia Pac showing early positive signs. New 3 Add multifocal launch delivered double-digit growth in the Americas.
PARAGARD: Grew 16% due to strong demand for single-hand inserter upgrade.
Global contact lens market: Trending towards premium offerings, benefiting MyDay portfolio. Market softness noted in China and certain EMEA regions.
Fertility market: Consumer spending remains tight, especially in Asia Pac. Positive signs include improving cycle activity in the U.S. and growing global clinic interest in new technology.
Reorganization and integration: Completed significant reorganization and integration work, unlocking $50 million in annual pretax savings starting fiscal 2026.
Free cash flow: Delivered $150 million in Q4, exceeding expectations. Fiscal 2026-2028 target raised to over $2.2 billion.
Share repurchase plan: Repurchased nearly $200 million in Q4, with a total fiscal year repurchase of $300 million. Plan increased to $2 billion.
Strategic review: Initiated formal strategic review to explore opportunities for long-term shareholder value.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Market softness in China and EMEA: The company experienced market softness in China and certain areas in EMEA, which impacted revenue growth. In China, there was a 28% decline driven by continued weakness in low-margin e-commerce channels.
Tariffs and product mix: Gross margins declined marginally due to tariffs and unfavorable product mix, which could continue to pressure profitability.
Consumer spending in fertility market: Consumer spending remains tight in the fertility market, especially in Asia Pacific, and clinics are managing spending carefully, which could impact growth in this segment.
Legacy product softness: There was softness in legacy products within the medical devices segment, which could hinder growth in this area.
Interest expense and Fed policy: Interest expense is expected to remain high at $85 million for fiscal 2026, with potential sensitivity to changes in Federal Reserve policy.
Reorganization and integration costs: The company incurred $89 million in charges related to reorganization and integration activities, which could temporarily impact financial performance.
Competitive pricing in low-margin channels: The company is not chasing aggressive pricing activity in low-margin e-commerce channels in China, which could limit market share in this region.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Expectations: For fiscal 2026, consolidated revenues are projected to be $4.3 billion to $4.34 billion, reflecting 4.5% to 5.5% organic growth. CooperVision's revenue is expected to be $2.9 billion to $2.925 billion, up 4.5% to 5.5% organically. CooperSurgical's revenue is expected to be $1.4 billion to $1.413 billion, up 4% to 5% organically.
Earnings Projections: Non-GAAP EPS for fiscal 2026 is projected to be $4.45 to $4.60, with strong operating margin improvement driven by operating expense leverage, offset by lower gross margins due to tariffs and mix.
Free Cash Flow: Free cash flow for fiscal 2026 is expected to improve to $575 million to $625 million, driven by stronger operating cash flow from higher profits, working capital improvements, and lower one-time costs. From fiscal 2026 through 2028, the company expects to generate over $2.2 billion in free cash flow.
Capital Expenditures: CapEx is expected to decline on an absolute basis as CooperVision's investment cycle winds down. CapEx will normalize in fiscal 2027 to roughly 5% of revenues, covering both maintenance and growth investments.
Market Trends and Product Launches: The global contact lens market is trending toward premium offerings, benefiting the MyDay portfolio. Upcoming launches include MyDay, MiSight, and MyDay toric multifocal in 2026. MiSight is expected to grow 20% to 25% in fiscal 2026, with further strength in 2027 as product launches gain traction. The fertility market shows early positive signs, including improving cycle activity in the U.S. and growing global clinic interest in new technology.
Operational Changes: The company completed significant reorganization and integration work, unlocking annual pretax savings of roughly $50 million starting in fiscal 2026. These savings will support investments, stock repurchases, and debt reduction.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Share Repurchase in Q4 2025: Repurchased nearly $200 million of stock in fiscal Q4, bringing total fiscal year repurchases to almost $300 million, which is roughly 2/3 of the 2025 free cash flow.
Share Repurchase Plan for Fiscal 2026: Expect to allocate a similar percentage of free cash flow to share repurchases as in 2025, with the remaining portion targeted to debt paydown.
Board Authorization for Share Repurchase: Board authorized an increase in the share repurchase plan to $2 billion in September 2025.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Did you give a number for how much clariti was down?
A:Clariti was down a couple of percent this quarter, approaching $400 million this year. It remains a sizable product line with ongoing repositioning efforts in Asia Pacific and new product launches like the 3 Add multifocal in the U.S.
Q:Do you see MyDay gross margins eventually getting to clariti gross margin levels?
A:Brian Andrews stated that gross margins for daily silicone hydrogel lenses are below CooperVision's gross margins. While there is pressure on gross margins, revenue per patient and gross profit dollars are higher for daily silicone hydrogels, which supports operating margin expansion and earnings growth.
Q:Can you reconcile the 5% growth in calendar Q3 with the 3.2% in fiscal Q4?
A:The discrepancy was due to the overlap at the beginning of the quarter, not the end. October was a good month.
Q:Could you talk about the strategic review and its timeline?
A:The strategic review is underway, with an update expected during the next earnings call in March unless something material happens earlier. The review aims to explore options to drive shareholder value.
Q:Has your position on splitting up CVI and CSI changed?
A:Albert White's position has not changed. The focus remains on driving long-term shareholder value through actions like reorganization, stock buybacks, and cash flow improvements.
Q:What are your contact lens market growth expectations for 2026?
A:The market is expected to grow 4% to 5%, with global pricing for next year around 1%. The growth assumption is based on recent market performance and pricing trends.
Q:What is the outlook for APAC growth in fiscal 2026?
A:APAC growth is expected to improve as challenges in the pure-play e-commerce channel and China subside. The region's impact on overall business will be smaller in 2026 compared to 2025.
Q:Why is the revenue growth guide for fiscal 2026 back-end loaded?
A:The back-end loading is due to momentum in MyDay sales, additional private label contracts, and easier comparisons in CooperSurgical's fertility business.
Q:What is driving the improved free cash flow outlook?
A:The improvement is driven by consistent execution, reduced CapEx in CooperVision, and completion of significant business activities like the new R&D facility. Free cash flow is expected to exceed $2.2 billion.
Q:Are share repurchases included in the fiscal 2026 earnings guidance?
A:No, share repurchases are not included in the guidance range, although 2/3 of free cash flow is targeted for repurchases.
Q:Why was Colleen chosen as the next Chairman?
A:Colleen was chosen due to her extensive experience, global and branding expertise, and contributions like introducing TSR to align executive compensation with shareholder returns.
Q:What is the willingness to take short-term dilution for long-term value in the strategic review?
A:The company is evaluating all alternatives to drive long-term shareholder value, including potential short-term impacts.
Q:How is operating margin leverage achieved despite gross margin pressure in fiscal 2026?
A:Operating margin leverage is achieved through controlled SG&A growth and efficiencies from prior reorganization efforts.
Q:What are the catalysts for CVI's market share gains in calendar Q4?
A:The catalysts include improved performance compared to a weak prior year, driven by MyDay momentum and other product launches.
Q:What are the synergies and dissynergies of having CVI and CSI under one umbrella?
A:Synergies are mainly in back-office functions, while dissynergies include potential tax and operational inefficiencies. Capital allocation has not been an issue.
Q:What are the assumptions for PARAGARD growth in fiscal 2026?
A:PARAGARD is expected to grow flat to low single digits, factoring in potential competition. Margins have slightly decreased due to the single-hand inserter launch.
Q:What is the outlook for MiSight and myopia management in fiscal 2026?
A:MiSight is expected to grow 20%-25%, with potential upside from new launches like MiSight on the silicone hydrogel platform and expansion into Japan.
Q:What is the impact of private label contracts on fiscal 2026?
A:Private label contracts, especially in APAC, EMEA, and the U.S., are expected to drive growth, with momentum building in Q3 and Q4.
Q:What are the expectations for fertility business growth in fiscal 2026?
A:Fertility is expected to grow mid-single digits, with easier comparisons and new technology upgrades driving growth.
Q:What are the new product launches and innovations in the pipeline?
A:New launches include MyDay, MiSight on silicone hydrogel, and genomics tests in fertility. Additional material and technology innovations are in development.
Q:Review of Unclear Management Responses
A:Management avoided providing specific gross margin details for individual product lines and did not comment on the potential synergies or antitrust risks in the contact lens space. Additionally, they did not provide detailed timelines or specifics on strategic review outcomes, citing ongoing evaluations.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
APAC region
Al opening
Americas FRPs
Americas record
Asia Pac
Biofinity Americas
Chair
Conference
Cooper Companies
CooperSurgical
Energys
MyDay toric
apple
clariti
clinic interest
commitment
consensus expectation
customer
deal
expectation market
expectation momentum
fertility market
genomics
line market
momentum launch
premium
priority
share gain
share repurchase
shareholder value
sign
softness
stock
term shareholder
traction
transition
weakness
win
COO Transcript
The Cooper Companies, Inc. (COO) Q2 2026 Earnings Call Transcript
Neutral6-5
Profound Medical Corp. (PRN:CA) Q4 2025 Earnings Call Transcript
Unknown3-6
The earnings call revealed a 15% revenue increase and improved gross margins, but the company still reported a net loss. The lack of strategic initiatives and forward-looking guidance, coupled with a 5% rise in operating expenses, tempers the positive financial metrics. The acknowledgment of risks without specific mitigation strategies adds uncertainty. Overall, the mixed financial performance and absence of strategic discussion suggest a neutral sentiment.
The Cooper Companies, Inc. (COO) Q1 2026 Earnings Call Transcript
Positive3-6
The earnings call highlights strong financial performance with a 7% revenue increase and 8% EPS growth. Despite a slight decrease in gross margin, operating margins remain stable. Positive projections for revenue and margin improvements, alongside strategic growth in contact lens and fertility segments, contribute to a positive outlook. The absence of discussed risks and stable capital expenditures further support this sentiment. However, the lack of specific shareholder return plans slightly tempers the overall positivity.
The Cooper Companies, Inc. (COO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-14
COO Slides
COO Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
